CION Ameerpet
If your diffuse large B-cell lymphoma has come back, or never fully responded, being here does not mean options have run out. This guide explains relapsed and refractory DLBCL clearly — and how CION re-sets the plan with a repeat biopsy, restaging and second-line treatment.
If you have been told your diffuse large B-cell lymphoma (DLBCL) is relapsed or refractory, the first thing to know is what those words describe — because they shape what happens next.
Refractory DLBCL means the lymphoma did not fully respond to first-line treatment, or it grew while treatment was still being given. The disease is resistant. Relapsed DLBCL means the lymphoma first responded and went into remission, then came back later — this is often what people mean when they say their DLBCL came back. Both situations share a common next step: a careful re-assessment and a plan for second-line lymphoma treatment.
Around one in three people treated for DLBCL will face relapsed or refractory disease. It is an aggressive, fast-growing lymphoma — but crucially, second-line treatment often still aims to cure, not merely to control. This page explains why a repeat biopsy matters, what the treatment options are, and how CION coordinates the more intensive parts of care. For the wider picture, see our Lymphoma hub.
Unlike many slow-growing (indolent) lymphomas, where treatment usually controls rather than cures the disease, relapsed and refractory DLBCL is often still treated with curative intent. Modern second-line pathways — intensive salvage chemotherapy followed by stem-cell transplant, or cellular immunotherapy such as CAR T-cell therapy — have meaningfully improved outcomes for people whose disease returns. (Source: NCCN B-Cell Lymphomas guidelines and ESMO DLBCL clinical practice guidelines.)
After finishing treatment, most people are followed with regular reviews. Relapse can show up between visits, so it helps to know the warning signs. Any of these after a remission warrants prompt specialist review — not panic, but a swift check.
A fresh, painless swelling of a lymph node — in the neck, armpit, groin or elsewhere — or an old node that starts enlarging again. This is the most common way relapsed DLBCL first announces itself.
Sweats heavy enough to soak the sheets and require a change of clothes, distinct from feeling warm. These "B symptoms" can signal recurrent lymphoma activity.
Losing weight without trying, or recurring fevers with no clear infection. Alone these have many causes, but together with a lump or sweats they deserve a scan.
Persistent, unusual tiredness after you had been recovering well. When it is new and progressive after a remission, it is worth flagging to your team early.
These symptoms are not proof of relapse and often have ordinary causes. But when they are new and persistent after DLBCL treatment, a prompt review — and usually a scan — is the safe course.
Relapsed and refractory DLBCL is one of the situations where getting the plan right — quickly, but thoroughly — matters most. Here is how CION approaches it.
We do not assume a lump is relapse. A repeat biopsy and restaging confirm recurrent DLBCL and re-check its current biology before any second-line plan is chosen.
Every relapsed case is reviewed by a multidisciplinary team — haematology, medical and radiation oncology and pathology — so the plan reflects more than one specialist's view.
CION delivers salvage chemotherapy, antibody-based therapy and radiation directly, and coordinates CAR T-cell therapy and stem-cell transplant through accredited partner facilities.
You get a free written second opinion and clear, up-front costs. We aim for a plan built around healing, not billing — with realistic expectations at every step. See our lymphoma hospital in Hyderabad.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Just learned your DLBCL has come back, or that it did not respond to first-line treatment? CION's lymphoma team can re-assess and set a clear second-line plan — meet our lymphoma doctors in Hyderabad.
When DLBCL is suspected of returning, the plan starts with a fresh, careful assessment — not straight to treatment. CION delivers the imaging, biopsy coordination, molecular testing and tumour-board review directly.
A repeat biopsy at relapse does three jobs. It confirms the new growth really is recurrent lymphoma rather than an infection or a second, unrelated problem. It lets the pathologist re-check the exact subtype and current molecular biology — DLBCL can change over time, and knowing today's cell-of-origin, MYC and BCL2 status guides treatment. And it confirms whether markers such as CD20 are still present, which matters for antibody-based and cellular therapies. NCCN and ESMO both support tissue confirmation at relapse wherever it is safely feasible.
A PET-CT restages the disease — showing where the lymphoma has returned and how active it is. This maps out whether relapse is localised or widespread, which strongly influences whether a localised treatment (such as radiation) or a systemic approach is right, and it provides the baseline against which future response is measured.
How long your first remission lasted is one of the most important pieces of information. An early, treatment-resistant relapse generally behaves more aggressively than a relapse that occurs after several disease-free years, and this timing helps the tumour board weigh the intensity of second-line options.
Second-line and later treatment is chosen from several families. The right one depends on how long your remission lasted, your age and fitness, and the current biology of the lymphoma. We describe options by class here; for specific refractory DLBCL treatment regimen names, see our Lymphoma Treatment in Hyderabad page. Every plan is set by the tumour board.
Intensive multi-drug salvage chemotherapy aims to get the lymphoma back into remission. For fit patients, it often serves as a bridge to a stem-cell transplant. CION's medical oncology team delivers this systemic therapy directly, with full supportive care.
An autologous stem-cell transplant uses high-dose chemotherapy followed by a rescue with your own previously collected stem cells, usually after salvage chemotherapy has produced a good response. This intensive treatment is coordinated through an accredited partner facility, with CION managing the assessment, referral and follow-on care.
CAR T-cell therapy re-engineers your own T-cells to recognise a lymphoma marker (such as CD19) and can work even when chemotherapy has stopped controlling the disease. Like transplant, it is arranged via a coordinated referral to an accredited partner facility. Learn more on our CAR T-cell therapy for lymphoma page.
When CD20 remains present, anti-CD20 monoclonal antibody therapy and antibody-drug conjugates are options CION delivers directly, sometimes combined with chemotherapy. These can be valuable for patients who are not candidates for transplant.
Where relapse is confined to one area, or to relieve a specific symptom, precision radiation (IMRT) — delivered directly at CION — can be an effective and well-tolerated part of the plan.
A repeat biopsy at relapse can change the diagnosis itself. Because DLBCL biology can shift over time — or because an indolent lymphoma can transform into aggressive disease — re-sampling tissue sometimes reveals a different subtype or new molecular features than the original diagnosis. This is exactly why NCCN and ESMO support tissue confirmation at relapse whenever it is safely feasible: the current biology, not the old report, should guide second-line treatment. (Source: NCCN B-Cell Lymphomas guidelines; ESMO DLBCL clinical practice guidelines.)
It is natural to want a number, but the honest answer is that the outlook at relapse varies widely by individual. It depends most on how long your first remission lasted and how the disease responds to second-line treatment — an early, treatment-resistant relapse is more challenging than a late one.
To give context: published series report first-line DLBCL cure rates of roughly 60–70%, while aggressive Hodgkin lymphoma sits higher at around 80–90% — figures that come from large population studies (as summarised in NCCN and ESMO guidance) and that vary by stage, age and biology. For people whose DLBCL returns, modern cellular therapies such as CAR T-cell therapy have meaningfully improved outcomes compared with a decade ago. What these numbers cannot do is predict any one person's result — your own figures depend on your specific situation.
Most relapses occur within the first two years, and the chance of relapse falls the longer a remission lasts. For a fuller discussion, see our DLBCL survival & prognosis page. If your relapse followed a slow-growing lymphoma, our page on follicular lymphoma transformation to aggressive disease may also be relevant.
A relapsed or refractory DLBCL plan involves finely balanced choices, and a second opinion is especially worthwhile in a few situations:
CION offers a dedicated, free written second-opinion service. You deserve a plan built around healing, not billing — with transparent costs explained up front. Request your free second opinion or call 18002028726. You can also explore related B-cell subtypes such as double-hit / high-grade B-cell lymphoma and primary mediastinal B-cell lymphoma.
Get a free written second opinion from CION's lymphoma tumour board — especially valuable if a repeat biopsy has not yet been arranged, or before committing to transplant or CAR T-cell therapy.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.These two words describe how diffuse large B-cell lymphoma (DLBCL) has behaved after first-line treatment. Refractory DLBCL means the lymphoma never fully responded to initial therapy, or progressed while still on it — the disease is resistant. Relapsed DLBCL means the lymphoma responded and went into remission first, then came back weeks, months or years later. Both situations are grouped together because the next steps overlap: a fresh assessment, usually a repeat biopsy to confirm the disease, restaging scans, and a plan for second-line treatment. About one in three people with DLBCL will face relapsed or refractory disease, so being here does not mean options have run out — it means the plan is being re-set with clear intent.
Yes. When DLBCL comes back, the goal of second-line treatment often remains cure, not just control — which sets DLBCL apart from many slow-growing lymphomas. The right path depends on how long the remission lasted, your age and fitness, and where the disease has returned. For fit patients, an intensive approach followed by a stem-cell transplant (coordinated through an accredited partner facility) is a standard route. For others, or when the disease is resistant, cellular immunotherapy such as CAR T-cell therapy or antibody-based treatment may be more appropriate. Because these decisions are finely balanced, CION reviews every relapsed case at a multidisciplinary tumour board before recommending a plan. The most important step now is a prompt, thorough re-assessment.
A repeat biopsy at relapse is important for a few reasons. First, it confirms that the growth or symptom really is recurrent lymphoma and not an infection or a second, unrelated problem. Second, it lets the pathologist re-check the exact subtype and molecular markers — DLBCL can change its biology over time, and knowing the current cell-of-origin, MYC and BCL2 status guides which second-line treatment is likely to work. Third, it confirms whether markers such as CD20 are still present, which matters for antibody-based and cellular therapies. NCCN and ESMO guidance both support tissue confirmation at relapse wherever it is safely feasible. CION coordinates the biopsy and the molecular testing, then reviews the results at tumour board.
Second-line and later treatment is chosen from several families, described here by class rather than brand. Salvage chemotherapy (intensive multi-drug regimens) aims to get the disease back into remission, often as a bridge to a stem-cell transplant, which is coordinated through an accredited partner facility. Cellular immunotherapy — CAR T-cell therapy — re-engineers your own immune cells and is also delivered via a coordinated referral. Antibody-based and targeted therapies, including anti-CD20 monoclonal antibodies and antibody-drug conjugates, are options CION delivers directly. Radiation (IMRT) may treat a localised relapse or control symptoms. For specific regimen names, see our Lymphoma Treatment in Hyderabad page. Every plan is set by the tumour board.
Both are intensive cellular treatments used in relapsed or refractory DLBCL, and at CION both are coordinated through accredited partner facilities — not delivered in-house. An autologous stem-cell transplant uses high-dose chemotherapy to wipe out lymphoma, then rescues the bone marrow with your own previously collected stem cells; it usually follows successful salvage chemotherapy. CAR T-cell therapy takes your own T-cells, re-engineers them in a laboratory to recognise a lymphoma marker (such as CD19), and returns them to attack the disease; it can work even when chemotherapy has stopped controlling the lymphoma. The choice depends on how the disease responded to salvage treatment, your fitness, and the timing of the relapse. The tumour board weighs these factors together. Read more about CAR T-cell therapy for lymphoma.
Most DLBCL relapses happen within the first two years after treatment; relapse becomes progressively less likely the longer a remission lasts, and a relapse after several disease-free years is uncommon. The outlook at relapse varies widely by individual and depends heavily on how long the first remission lasted and how the disease responds to second-line treatment — early, treatment-resistant relapse is more challenging than a late one. Published series report first-line DLBCL cure rates of roughly 60–70%, and modern cellular therapies have meaningfully improved outcomes for many people whose disease returns (per NCCN and ESMO guidance). These are population figures, and individual outcomes vary. A repeat biopsy and restaging give the clearest picture — see our DLBCL survival & prognosis page.
Do not wait. Book a prompt review with a lymphoma specialist and bring every report you have — your original biopsy and pathology, previous PET-CT and other scans, treatment summary and dates of remission. New or growing lumps, drenching night sweats, unexplained weight loss, fevers or fatigue after a remission all warrant urgent assessment. At CION you can request a free written second opinion on your existing reports before any repeat tests are done. If confirmed, the team arranges a repeat biopsy, restaging scans and molecular testing, then sets a second-line plan at the tumour board. Speed matters in relapsed DLBCL, but so does getting the plan right — both are the point of an early specialist review. You can also call 1800 202 8726.
Browse our complete guide to lymphoma — symptoms, diagnosis, Hodgkin and non-Hodgkin subtypes, treatment, genetics, prognosis, survivorship and cost. Tap any topic to read more.